PMC:7534795 / 1621-1890 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T13","span":{"begin":109,"end":117},"obj":"Disease"},{"id":"T14","span":{"begin":233,"end":241},"obj":"Disease"}],"attributes":[{"id":"A13","pred":"mondo_id","subj":"T13","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A14","pred":"mondo_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"lites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T74203","span":{"begin":246,"end":251},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"}],"text":"lites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T25","span":{"begin":40,"end":45},"obj":"Chemical"},{"id":"T26","span":{"begin":59,"end":67},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_26208"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_60809"}],"text":"lites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T57624","span":{"begin":175,"end":187},"obj":"http://purl.obolibrary.org/obo/GO_0009405"}],"text":"lites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms"}

{"project":"LitCovid-PubTator","denotations":[{"id":"41","span":{"begin":118,"end":126},"obj":"Species"},{"id":"50","span":{"begin":36,"end":45},"obj":"Chemical"},{"id":"61","span":{"begin":109,"end":117},"obj":"Disease"},{"id":"62","span":{"begin":191,"end":219},"obj":"Disease"},{"id":"63","span":{"begin":233,"end":241},"obj":"Disease"}],"attributes":[{"id":"A41","pred":"tao:has_database_id","subj":"41","obj":"Tax:9606"},{"id":"A50","pred":"tao:has_database_id","subj":"50","obj":"MESH:D015525"},{"id":"A61","pred":"tao:has_database_id","subj":"61","obj":"MESH:C000657245"},{"id":"A62","pred":"tao:has_database_id","subj":"62","obj":"MESH:D002318"},{"id":"A63","pred":"tao:has_database_id","subj":"63","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"lites, it is reasonable to consider n-3 PUFAs as potential adjuvant therapies for the clinical management of COVID-19 patients. In this article, we provide an overview of the pathogenesis of cardiovascular complications secondary to COVID-19 and focus on the mechanisms"}